Europe injectable drugs market was valued at $104.8 billion in 2020 and will grow by 9.7% annually over 2020-2030 owing to the increasing prevalence of chronic diseases, rising use of self-administered Injectable formulations, technological advancements in drug development, and growing approvals of new injectable drugs such as COVID-19 vaccines.
Highlighted with 33 tables and 54 figures, this 111-page report Europe Injectable Drugs Market 2020-2030 by Molecule Type (Small, Large), Drug Class (mAbs, Immunoglobulin, Insulin, Vaccines, Cytokines, Peptide Hormone, Blood Factors), Delivery (Pre-filled Syringe, Infusions, Others), Application (Oncology, Infectious Diseases, Autoimmune, Cardiovascular), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, E-Commerce), and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire Europe injectable drugs market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).
In-depth qualitative analyses include identification and investigation of the following aspects:
Market Structure
Growth Drivers
Restraints and Challenges
Emerging Product Trends & Market Opportunities
Porters Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe injectable drugs market in every aspect of the classification from perspectives of Molecule Type, Drug Class, Delivery, Application, Distribution Channel, and Country.

Based on Molecule Type, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
Small Molecule
Large Molecule

Based on Drug Class, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
Monoclonal Antibodies (mAbs)
Immunoglobulin
Insulin
Vaccines
Cytokines
Peptide Hormone
Blood Factors
Other Drug Classes

Based on Delivery, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
Pre-filled Syringe
Infusions
Other Deliveries

Based on Application, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
Oncology
Infectious Diseases
Autoimmune Diseases
Cardiovascular Diseases
Pain
Neurology
Other Applications

Based on Distribution Channel, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
Hospital Pharmacy
Retail Pharmacy
E-Commerce

Geographically, the following national/local markets are fully investigated:
Germany
UK
France
Spain
Italy
Russia
Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of key national markets by Molecule Type, Drug Class, and Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Amgen Inc.
Baxter International Inc.
Eli Lilly and Company
Gilead Sciences Inc.
GlaxoSmithKline PLC
Johnson & Johnson
Merck & Co. Inc.
Moderna, Inc.
Novartis AG
Novo Nordisk AS
Pfizer Inc.
Sanofi SA
Teva Pharmaceuticals Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)